Celgene – DNDi Partnership

Partnership objective

The partnership aims to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs).

This partnership aims to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs). This partnership aims to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs). Copyright DNDi

Description of partnership activities and how they address needs and challenges

Since 2011, Celgene Global Health (CGH) and DNDi have collaborated on the screening of CGH’s compound library for activity against NTDs.

In 2014, this collaboration was expanded towards the identification and optimization of potential therapeutic candidates for several of the world’s most neglected diseases, including leishmaniasis, sleeping sickness, Chagas disease, river blindness, and elephantiasis.

The Research Collaboration Agreement established between the two partners focuses on the lead optimization stage of research, with CGH providing novel compounds of interest for the targeted diseases and using its target-identification and drug-discovery technology platforms to progress these compounds up to identification of clinical candidates. DNDi will take the lead on hit confirmation and coordinate and conduct hit expansion, hit-to-lead compound work, and subsequent lead optimization work.

The agreement ensures that the result of the joint research enables DNDi to operate within the scope of neglected communicable diseases and in all endemic countries without the need to pay royalties or license fees. Celgene has the right of first negotiation to become DNDi’s clinical development, manufacture and distribution partner and commits to support broad access to patients in need in endemic countries.

In June 2016, Celgene became the fifth company to join the ‘Negelcted Tropicla Diseases Drug Discovery Booster’ consortium, an initiative set up one year before that aims to accelerate and cut the cost of early stage drug discovery for leishmaniosis and Chagas disease. 

Partnership information

Company(ies) Celgene

Partner(s) Drugs for Neglected Diseases initiative (DNDi)

Type of Partner(s) PDPs

Therapeutic Focus Neglected Tropical Diseases

Disease(s) Chagas Disease, Human African Trypanosomiasis (Sleeping Sickness), Leishmaniasis, Lymphatic Filariasis

Program Type(s) Research & Development - Development of Treatments

Targeted Population(s) Patients in needs of treatment

Region(s)

Number of Countries 1

Country(ies) Worldwide

Start Date 2011

More information Press Release

Anticipated completion date Ongoing

« The expertise Celgene has developed over the past years with its global health focus will be a great asset to drug discovery for neglected tropical diseases »

Dr Bernard Pécoul, Executive Director of DNDi